+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Urokinase-type plasminogen activator and its receptor are increased in the vessel wall following experimental angioplasty



Urokinase-type plasminogen activator and its receptor are increased in the vessel wall following experimental angioplasty



European Heart Journal 17(ABSTR Suppl. ): 98




Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 034144236

Download citation: RISBibTeXText


Related references

Changes in Vessel Wall Urokinase Type Plasminogen Activator and Its Receptor following Experimental Angioplasty. Clinical Science 91(S35): 9p.1-9p, 1996

Time sequence of changes in vessel wall tissue plasminogen activatory, urokinase-type plasminogen activatory and its receptor following experimental angioplasty. Fibrinolysis 10(Suppl. 3): 73, 1996

Overexpression of urokinase receptor and cell surface urokinase-type plasminogen activator in the human vessel wall with different types of atherosclerotic lesions. Blood Coagulation & Fibrinolysis 15(5): 383-391, 2004

Changes in urokinase-type plasminogen activator and plasminogen activator inhibitor-1 activities within the vessel wall during the development of intimal hyperplasia. European Heart Journal 18(ABSTR Suppl. ): 227, 1997

Urokinase-type plasminogen activator/type-2 plasminogen-activator inhibitor complexes are not internalized upon binding to the urokinase-type-plasminogen-activator receptor in THP-1 cells: Interaction of urokinase-type plasminogen activator/type-2 plasminogen-activator inhibitor complexes with the cell surface. European Journal of Biochemistry 233(2): 514-519, 1995

The effect of surgical preparation of saphenous vein coronary artery conduits on vessel wall urokinase-type plasminogen activator and plasminogen activator inhibitor-1. Clinical Science (London) 90(2): 23P-24P, 1996

Differential effects of acute and chronic wound fluids on urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor, and tissue-type plasminogen activator in cultured human keratinocytes and fibroblasts. Wound Repair & Regeneration 9(4): 314-322, July-August, 2001

Nipple aspirate fluid expression of urokinase-type plasminogen activator, plasminogen activator inhibitor-1, and urokinase-type plasminogen activator receptor predicts breast cancer diagnosis and advanced disease. Annals of Surgical Oncology 10(8): 948-953, 2003

Physiological and pathological changes of plasma urokinase-type plasminogen activator, plasminogen activator inhibitor-1, and urokinase-type plasminogen activator receptor levels in healthy females and breast cancer patients. Breast Cancer Research & Treatment. 49(1): 41-50,, 1998

Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis. Journal of Urology 174(2): 461-465, 2005

Urokinase-type plasminogen activator , urokinase-type plasminogen activator receptor , plasminogen activator inhibitor type 1 , type 2 , and tissue-type plasminogen activator in breast cancer cells. Fibrinolysis & Proteolysis 14(Suppl. 1): 38, 2000

Effects of hypoxia and reoxygenation on the expression levels of the urokinase-type plasminogen activator, its inhibitor plasminogen activator inhibitor type-1 and the urokinase-type plasminogen activator receptor in human head and neck tumour cells. Oncology Reports 17(5): 1259-1268, 2007

Expression of tissue plasminogen activator, urokinase plasminogen activator, and urokinase plasminogen activator receptor on the lateral wall of the cochlea. Journal of the Osaka City Medical Center 56(1-2): 9-16, 2007

Epithelial tissue-type plasminogen activator expression, unlike that of urokinase, its receptor, and plasminogen activator inhibitor-1, is increased in chronic venous ulcers. British Journal of Dermatology 151(6): 1189-1196, 2004

Immunohistochemical localization of urokinase-type plasminogen activator, type-1 plasminogen-activator inhibitor, urokinase receptor and alpha(2)-macroglobulin receptor in human breast carcinomas. International Journal of Cancer 66(4): 441-452, 1996